Aspen marked World Diabetes Day by highlighting the alarming economic, social, productivity and reduced life expectancy impact that diabetes is having on South Africa
Aspen marked World Diabetes Day by highlighting the alarming economic, social, productivity and reduced life expectancy impact that diabetes is having on South Africa
Aspen Pharmacare Holdings has reported financial results for the year ended 30 June 2025, with strong momentum in Commercial Pharmaceuticals and a modified Manufacturing strategy.
Aspen Pharmacare Holdings has reported positive Group interim financial results for the six months ended 31 December 2024.
Aspen has announced the availability of Lilly’s tirzepatide, marketed globally as Mounjaro®, a therapeutic option available to physicians for the treatment of Type II diabetes.
Aspen and SEMDSA earlier today raised awareness around the alarming rise of non-communicable diseases, particularly diabetes, in recognition of World Diabetes Day.
JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid Group financial results for the year ended 30 June 2024.
Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912
Medical Careline (South Africa) 0800 118 088
